<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="734">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03097315</url>
  </required_header>
  <id_info>
    <org_study_id>CLS1001-302</org_study_id>
    <nct_id>NCT03097315</nct_id>
  </id_info>
  <brief_title>Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis</brief_title>
  <acronym>AZALEA</acronym>
  <official_title>Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clearside Biomedical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clearside Biomedical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label safety study of suprachoroidal triamcinolone acetone injectable suspension in
      patients with non-infectious uveitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, open-label, multi-center study to assess the safety of 4 mg of CLS-TA
      administered via suprachoroidal injection for the treatment of subjects with non-infectious
      uveitis.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), grouped by organ system, relatedness to study medication, and severity</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Uveitis</condition>
  <condition>Uveitis, Posterior</condition>
  <condition>Uveitis, Anterior</condition>
  <condition>Uveitis, Intermediate</condition>
  <condition>Panuveitis</condition>
  <arm_group>
    <arm_group_label>4mg CLS-TA Suprachoriodal Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4mg CLS-TA Suprachoriodal Injection Suprachoroidal injection of 40 mg/mL (4 mg in 100 μL) of CLS-TA</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>4mg CLS-TA Suprachoriodal Injection</intervention_name>
    <description>CLS-TA, 4 mg in 100 microliters, will be administered as a single injection at 2 timepoints</description>
    <arm_group_label>4mg CLS-TA Suprachoriodal Injection</arm_group_label>
    <other_name>Triamcinolone Acetonide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-infectious uveitis (pan, anterior, intermediate and posterior)

          -  ETDRS BCVA score of ≥ 5 letters read in the study eye

        Exclusion Criteria:

          -  Any active ocular disease or infection in the study eye other than uveitis

          -  Intraocular pressure &gt; 22 mmHg or uncontrolled glaucoma in the study eye

          -  Any uncontrolled systemic disease that, in the opinion of the Investigator, would
             preclude participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Kissner, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clearside Biomedical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellie Smith</last_name>
    <email>ellie.smith@clearsidebio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nichole Wilkes</last_name>
    <email>nichole.wilkes@clearsidebio.com</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>March 27, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uveitis</keyword>
  <keyword>UME</keyword>
  <keyword>Posterior Uveitis</keyword>
  <keyword>Anterior Uveitis</keyword>
  <keyword>Intermediate Uveitis</keyword>
  <keyword>Panuveitis</keyword>
  <keyword>Non-infectious Uveitis</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>Choroid</keyword>
  <keyword>Choroidal Injection</keyword>
  <keyword>Suprachoroidal</keyword>
  <keyword>Microneedle</keyword>
  <keyword>Microinjection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Uveitis</mesh_term>
    <mesh_term>Panuveitis</mesh_term>
    <mesh_term>Uveitis, Posterior</mesh_term>
    <mesh_term>Uveitis, Intermediate</mesh_term>
    <mesh_term>Pars Planitis</mesh_term>
    <mesh_term>Uveitis, Anterior</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
